CRISPR Therapeutics

crisprtx.com

CRISPR Therapeutics is pioneering a new era of medicines by developing gene-based therapies using its proprietary CRISPR/Cas9 gene-editing platform. The company has established a diverse portfolio across various disease areas, including hemoglobinopathies, oncology, diabetes, and cardiovascular disease. Their first-ever approved CRISPR-based therapy, CASGEVY™, targets sickle cell disease and transfusion-dependent beta thalassemia. With a commitment to patient advocacy and rapid translation of revolutionary technology into therapies, CRISPR Therapeutics is at the forefront of gene editing innovation, aiming to transform the lives of patients with serious diseases.